Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those ...

An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a ...

Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven't responded to oral ...

The Food and Drug Administration (FDA) has approved Spravato, a nasal spray developed by Johnson & Johnson, as a standalone ...

Fact checked by Nick Blackmer The Food and Drug Administration (FDA) has expanded its approval of a ketamine nasal spray, ...

The Food and Drug Administration (FDA) approved Johnson & Johnson’s ketamine-derived nasal spray to help millions of U.S. patients suffering from severe depression. Spravato, approved as a ...

The FDA approves Spravato, a nasal spray derived from Ketamine, to help some people treat depression. Dr. Bill Hartman from UW Health shares more.

Because it is still awaiting approval, Medicare does not typically cover the use of ketamine infusion for treating mental health conditions. However, they may cover the FDA-approved nasal spray ...